Navigation Links
Accera, Inc. to Present at Upcoming Investor Conferences
Date:3/25/2009

BROOMFIELD, Colo., March 25 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) disorders, today announced that the company will be participating at two upcoming healthcare investor conferences.

Dr. Steve Orndorff, Founder, President and CEO, will speak at the 2nd Annual BIO Venture Conference on April 1 at 10:15 a.m. EDT at the Sheraton Boston Hotel in Boston, MA. On April 9 at 11:30 a.m. PDT, he will present at the C21 BioVentures Conference at the Meritage Resort in Napa Valley, CA.

In early March, the company launched Axona(TM), a medical food available only by prescription for mild-to-moderate Alzheimer's disease. Dr. Orndorff will provide an overview of Accera and its technology pipeline and also provide an update on the successful nationwide launch of Axona.

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops product breakthroughs in treating central nervous system disorders. Accera's novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated treatments. Through its proprietary scientific platform, Accera is developing therapies that address metabolic deficiencies by providing an alternative energy source to the brain.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies.

    Contacts:
    Media:                                  Investors:
'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
2. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
3. Accera, Inc. Completes $35 Million Series C Financing
4. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
5. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
6. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
7. Avicena Group to Present at Noble Financial Conference
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Calif., Oct. 10 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... on Monday, October 13, to provide an update on ... stroke.,Hosting the call will be Paul E. Freiman, president ... officer., -- Date: Monday, October 13, ...
... effects of, recombinant lactoferrin (tradename: Lacromin) in mammalian ... leading to a significant boost ... A recently published study,in the scientific journal In Vitro ... see, http://www.Lacromin.com ) is a strong growth factor for ...
... CORPUS CHRISTI, Texas, Oct. 10 CSMG,Technologies, ... management,company, announced the company has received approval ... on a key divisional application for "Bonding ... Electric Current,Therethrough" for CSMG Technologies subsidiary Live ...
Cached Biology Technology:Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program 2New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 3
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... is pleased to name the latest recipients of its ... of Hospital for Special Surgery (HSS), Dipyaman Ganguly, PhD ... of the Feinstein Institute at North Shore-Long Island Jewish ... S.L.E. Lupus Foundation,s lifetime investment in New York City-based ...
... premature aging of immune cells, which may make people more ... new UCSF-led study. The findings indicate that accelerated ... is dependent upon how long someone is depressed, particularly if ... March 2011 by the journal PLoS One and ...
... -- Companies looking to engineer an eco-friendly diesel fuel have ... University researchers, making petroleum diesel completely green would not only ... green. "Fossil fuels are limited, and since we can,t ... are looking for alternative fuel sources like algae," said Peter ...
Cached Biology News:S.L.E. Lupus Foundation announces new grants to further NYC scientists' leadership in lupus research 2S.L.E. Lupus Foundation announces new grants to further NYC scientists' leadership in lupus research 3Study finds link between chronic depression and accelerated immune cell aging 2Study finds link between chronic depression and accelerated immune cell aging 3Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 2Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 3Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 4